Qiagen NV (QGEN) Expected to Post Quarterly Sales of $339.33 Million
Equities research analysts predict that Qiagen NV (NASDAQ:QGEN) will announce sales of $339.33 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Qiagen’s earnings, with estimates ranging from $337.00 million to $342.20 million. Qiagen reported sales of $307.71 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.3%. The company is scheduled to report its next earnings report on Tuesday, May 1st.
According to Zacks, analysts expect that Qiagen will report full-year sales of $339.33 million for the current fiscal year, with estimates ranging from $1.54 billion to $1.56 billion. For the next financial year, analysts expect that the company will post sales of $1.69 billion per share, with estimates ranging from $1.67 billion to $1.72 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Qiagen.
Qiagen (NASDAQ:QGEN) last issued its earnings results on Wednesday, January 31st. The company reported $0.43 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.01. The company had revenue of $396.86 million during the quarter, compared to analysts’ expectations of $394.48 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%.
Shares of Qiagen stock traded down $0.60 during trading hours on Monday, reaching $33.00. The company’s stock had a trading volume of 318,049 shares, compared to its average volume of 1,129,532. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. The stock has a market cap of $7,770.00, a PE ratio of -336.00, a P/E/G ratio of 1.93 and a beta of 0.98. Qiagen has a 12 month low of $27.74 and a 12 month high of $36.34.
Qiagen declared that its board has authorized a share repurchase program on Wednesday, January 31st that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its stock is undervalued.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in QGEN. Citadel Advisors LLC grew its holdings in shares of Qiagen by 816.3% during the 4th quarter. Citadel Advisors LLC now owns 1,051,713 shares of the company’s stock worth $32,529,000 after purchasing an additional 936,936 shares during the period. Atlanta Capital Management Co. L L C grew its holdings in shares of Qiagen by 210.1% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock worth $41,400,000 after purchasing an additional 890,454 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Qiagen by 163.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 844,529 shares of the company’s stock worth $26,326,000 after purchasing an additional 523,453 shares during the period. Systematic Financial Management LP purchased a new position in shares of Qiagen during the 4th quarter worth $15,834,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Qiagen by 127.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 652,285 shares of the company’s stock worth $20,521,000 after purchasing an additional 365,732 shares during the period. Institutional investors and hedge funds own 62.23% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/qiagen-nv-qgen-expected-to-post-quarterly-sales-of-339-33-million/1956806.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.